Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
06 nov. 2023 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its third...
Elutia to Participate in a Panel Discussion at the Cantor Global Healthcare Conference
20 sept. 2023 08h30 HE
|
Elutia Inc.
SILVER SPRING, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President...
Elutia Announces Private Placement for Proceeds Up to $26 Million
19 sept. 2023 08h36 HE
|
Elutia Inc.
– Combined proceeds of financing and Orthobiologics divestiture potentially top $60 million – SILVER SPRING, Md., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company...
Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million
18 sept. 2023 16h08 HE
|
Elutia Inc.
– Transaction Reflects Increasing Strategic Focus on Proprietary Drug-Eluting Biomatrix Platform – SILVER SPRING, Md., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a...
Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08 sept. 2023 08h30 HE
|
Elutia Inc.
SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President...
Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices
06 sept. 2023 16h05 HE
|
Elutia Inc.
– Company to begin trading under new ticker symbol “ELUT” – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the...
Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures
30 août 2023 08h30 HE
|
Aziyo Biologics
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md.,...
Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company
14 août 2023 16h05 HE
|
Aziyo Biologics
Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of...
Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
31 juil. 2023 16h05 HE
|
Aziyo Biologics
SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between...
Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products
13 juil. 2023 16h30 HE
|
Aziyo Biologics
SILVER SPRING, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical...